Healthcare
Live Price
Offline$10.70
+0.00% today
1Y Change
-24.76%
Window
Jun 20, 2025 → Jun 12, 2026
Coverage: 252 bars · Jun 20, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vitrolife AB (publ) (VTRLY) is a Healthcare stock with a market cap of $14.67B and listed on OTC. The stock last traded around $10.70 and down 24.8% across the available one-year price window (Jun 20, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -10.4%, EPS growth of -1017.9%, a dividend yield of 0.0%. What stands out right now is revenue -10.4%, EPS -1017.9%, free cash flow -62.2% with operating margin 18.0% and ROIC 5.7%. Valuation sits in the middle of the pack at price/sales 4.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VTRLY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VTRLY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VTRLY Max Drawdown
-48.79%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VTRLY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.7B
-48.0% YoY
FY Net Income
$341.0M
-13.5% YoY
Free Cash Flow
$321.9M
-41.4% YoY
Revenue Growth
-10.4%
EPS Growth
-1017.9%
Gross Margin
51.4%
Net Margin
-147.2%
Income statement
SEK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.2B | 3.6B | 3.5B | 3.2B | 1.7B |
| Gross Profit | 2.0B | 2.1B | 2.0B | 1.8B | 1.0B |
| Operating Income | 579M | 783M | -3.6B | 654M | 435M |
| EBITDA | 980M | 1.2B | -3.2B | 977M | 579M |
| Net Income | -4.7B | 513M | -3.9B | 394M | 341M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
SEK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 809M | 1.1B | 861M | 578M | 630M |
| Total Assets | 11.1B | 17.4B | 16.3B | 20.6B | 19.4B |
| Total Liabilities | 3.2B | 3.8B | 3.6B | 3.8B | 4.1B |
| Shareholder Equity | 7.9B | 13.6B | 12.7B | 16.7B | 15.3B |
| Total Debt | 1.6B | 2.1B | 2.1B | 2.2B | 2.5B |
| Net Debt | 796M | 954M | 1.2B | 1.6B | 1.9B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
384M
-39.6% YoY
Capital Expenditures
62M
+28.2% YoY
Free Cash Flow
322M
-41.4% YoY
Key ratios
Gross Margin
51.4%
Operating Margin
18.0%
Net Margin
-147.2%
ROE
-47.1%
Debt / Equity
0.20x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.